News/Blogs
GLP-1 Employer Coverage and Benefits: What Plan Sponsors Need to Know
Rarely have drug classes forced plan sponsors to revisit their decisions as often as GLP-1s have. Plans that added weight management coverage two years ago have often seen utilization outpace forecasts, manufacturers open direct-to-consumer channels that undercut plan net cost, and Medicare begin covering drugs.
Updates to GLP-1 policies have a significant impact on plan design. These changes decide who qualifies, on what evidence, for how long, and at what share of cost.
Where GLP-1 Employer Coverage Stands in 2026
Coverage benchmarks for this drug class tend to vary and can contradict each other.
For example, Business Group on Health found that coverage for weight management among its employer members dropped from 72 percent in 2025 to 60 percent in 2026, according to its 2027 Employer Healthcare Strategy Survey. A separate 2026 Business Group on Health survey of 105 large employers put current weight management coverage at 67 percent, with only 72 percent of those employers saying they were likely to keep it in 2027.
KFF, however, reports a much lower national figure. Its 2025 Employer Health Benefits Survey found 19 percent of firms with 200 or more workers covering GLP-1s primarily for weight loss, rising to 43 percent among firms with 5,000 or more workers.
Why the Coverage Numbers Disagree
These surveys are actually not in conflict. They differ because they measure different populations. KFF draws a broad national sample that includes mid-size employers. Business Group on Health surveys its own membership, which skews toward very large and heavily advised organizations. Mercer sits between the two.
For benchmarking, match the survey to your own size band and funding arrangement before quoting a number to a benefits committee. A 200-employee self-funded manufacturer and a 40,000-employee health system are not looking at the same market.
What Is Actually Driving GLP-1 Cost
Unit prices have come down, but plan spend has not.
Roughly eight in ten employers report that GLP-1s are pushing their healthcare costs up and are already seeing utilization of obesity medications increase. Pharmacy has climbed to about 25 percent of total healthcare spend, with employer drug costs projected to rise 12 percent. The pressure is volume, not price per fill.
Claims data through 2023 showed plan drug spend on Wegovy alone climbing more than 500 percent in a single year, with GLP-1 agonist sales up 58.2 percent between December 2022 and December 2023. By 2025, GLP-1 therapies accounted for nearly 25 percent of total client costs across the book. Our full analysis of GLP-1s and plan drug spend covers the underlying claims detail.
The eligible population explains the rest. When a third of your covered users meet clinical criteria, small shifts can move the budget hard. Among the largest employers KFF surveyed, 59 percent said weight management use came in higher than expected.
Discontinuation Is a Clinical and Cost Problem
Early discontinuation is expensive in a specific way. The first weeks are titration doses, so a member who stops at week six has consumed plan dollars without reaching a therapeutic dose or a measurable clinical result.
Nothing about that spend converts into lower medical costs later. This is the waste that utilization management is actually trying to solve, and it is a stronger argument for clinical support programs than for blunt exclusion.
GLP-1 Prior Authorization Criteria and What They Should Cover
Prior authorization on this class is close to universal, and the mechanics of how a prior authorization program operates matters less to a plan sponsor than the criteria. Pay attention to how tightly those criteria are written and how rigorously they are enforced at reauthorization.
Clinical Eligibility
Most commercial criteria follow FDA labeling: a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition. The design choice depends on whether eligibility is attested or verified. Employers increasingly require objective biometric data rather than prescriber attestation, which closes the most common gap in these programs.
Documented Lifestyle Intervention
Criteria commonly require three to six months of documented participation in a structured weight management program, either before therapy starts or running alongside it. When well written, this requirement does two things at once. It filters out prescriptions written without clinical context, and it builds the behavioral scaffolding that persistence data requires.
Continuation and Reauthorization
Initial approvals typically run five or six months. Continuation usually requires documented weight loss from baseline, most often 5 percent. The operational detail that decides whether this works is baseline capture. If baseline weight is not recorded at the time therapy starts, the reauthorization gate has nothing to measure against and approvals default to automatic.
What Tight Criteria Actually Produces
Criteria are only as good as their decision-making outcomes, which is why approval rates matter. Serve You Rx reported a 67 percent approval rate across GLP-1 agonists in 2024, against a 69 percent average approval rate across all categories. Within that same 2024 data, fewer than half of prior authorization requests for GLP-1s indicated for type 2 diabetes were approved. This reflects the volume of requests written for weight management under a diabetes-labeled product, which is precisely what clinical criteria exist to catch. Serve You Rx has published more on how those criteria are applied in practice.
One caution belongs in every criteria discussion. Tighter criteria reduces volume, and reduced volume can reduce rebates. A program evaluated on rebate yield will look worse than it performs. Evaluate it on net cost per covered member instead, and confirm how your contract defines the terms for measuring.
Managing GLP-1 Cost Without Dropping Coverage
Exclusion is one option among several, and it is rarely the first worth testing.
- Revisit cost share. Business Group on Health found that 83 percent of employers run GLP-1s through the same cost-sharing structure as every other prescription. A dedicated tier or a coinsurance band is available to most plans and remains underused.
- Concentrate volume. A preferred agent approach gives the plan a stronger negotiating position than covering the class broadly at parity.
- Pair coverage with clinical support. Persistence determines whether this spend produces results, and unsupported members discontinue at high rates. Serve You Rx built its Cardiometabolic Program around that finding, combining GLP-1 medication management with behavioral therapy and nutritional guidance rather than treating the prescription as the whole intervention.
- Evaluate direct-to-consumer and direct-to-employer arrangements. Business Group on Health reports 16 percent of employers directing members to direct-to-consumer channels and 17 percent using direct-to-employer arrangements for 2027.
- Audit the contract. Pricing definitions, rebate pass-through language, and audit rights determine what a plan actually pays for this class, regardless of what the coverage policy says.
The direct-to-consumer option carries a tradeoff worth naming. As Mercer has noted, drugs purchased outside the pharmacy benefit bypass the clinical monitoring a PBM performs, including drug interaction and drug-disease checks. Plans moving in this direction should also model the rebate impact before the plan year starts.
Comparing Coverage Approaches
Most plans land in one of four postures.
| Coverage approach | What it looks like | Best fit for | Watch-outs |
|---|---|---|---|
| Broad coverage, standard utilization management | Covered for diabetes and weight management with a basic prior authorization and standard cost share | Employers using benefits as a recruiting lever with budget headroom | Utilization forecasts have run low across most plans. Budget for higher penetration than modeled. |
| Coverage with tightened clinical criteria | Biometric verification, required weight management program participation, continuation tied to documented results | Most mid-market self-funded plans | Administrative burden shifts to prescribers. Criteria that cut volume can also cut rebate dollars. |
| Weight management excluded, direct-to-consumer support offered | Diabetes coverage retained. Members buy weight management drugs through manufacturer channels, sometimes with employer funds | Employers that cannot absorb the trend but want to offer something | Purchases outside the pharmacy benefit skip clinical monitoring such as interaction checks. Rebate impact needs review. |
| Full exclusion for weight management | Diabetes and cardiovascular indications covered. No weight management coverage | Plans facing double-digit pharmacy trend with no offsetting budget | Expect member appeals and diagnosis shifting toward covered indications. Document the exclusion clearly in plan documents. |
GLP-1 coverage is no longer a single decision. It is a set of them, covering eligibility, evidence, duration, cost share, and channel. Plans that inherit default criteria from a vendor template will likely experience issues down the line without thorough research and investigation.
Serve You Rx works with plan sponsors on clinical criteria design and contract terms that make GLP-1 spend measurable. Connect with our team to review how your current program is performing.
Give your clients the insights they want.
Fill out the form below, and discover the Serve You Rx difference.
About Serve You Rx®
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for nearly 40 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.
